



ASX Announcement

15 May 2026

Share Purchase Plan Results

SYDNEY Australia, Friday 15 May 2026 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) confirms that the Share Purchase Plan (“**SPP**”) announced to the ASX on 30 April 2026 closed 5pm Friday, 8 May 2026. The Company received valid applications for 1,348,480 shares raising \$44,500 (before costs). The Directors have accepted all valid applications in full in accordance with the Prospectus dated 16 April 2026. The Applicants will also receive 674,229 free attaching options, exercisable at \$0.045 (4.5 cents), expiring 2.5 years from the date of issue (“**Options**”).

Under the SPP, shareholders in the Company registered in Australia and New Zealand on the record date of Friday, 27 March 2026 (“**Eligible Shareholders**”) were entitled to subscribe for up to \$30,000 of new fully paid ordinary shares (“**SPP Shares**”) in the Company at the issue price of \$0.033 (3.3 cents) per SPP Share. The Company reserves the right to place the SPP Shortfall which amounts to \$955,500.

The Shares will rank equally with existing shares in the Company. The SPP Shares are to be issued today.

Managing Director & CEO, John Kelly, commented:

“On behalf of the Board of Atomo Diagnostics Limited I wish to thank shareholders for their participation in the Company’s fund-raising initiatives via the Share Purchase Plan. With the raising complete the Company is in a strong position to move forward with its operational activities”.

~ ENDS ~

For more information, please contact:

John Kelly

Managing Director & CEO & Interim Chair

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

This announcement was authorised by the Board.



About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnosics.com